Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Kyowa Hakko Bio to Transfer Domestic Livestock, Aquaculture Business to ASKA
January 4, 2010
- Mail-Order Drug Market Down 22.7% in 2009
January 4, 2010
- Pharmacies Don't Need Wholesalers’Information Services: Mr Fukai of Nihon Chouzai
January 4, 2010
- Bendamustine's Efficacy Confirmed for Low-Grade NHL: SymBio
January 4, 2010
- Teva-Kowa Aims at 10% Share in Generics Market
January 4, 2010
- GSK Considers Disclosing All Payments to Med Institutions
January 4, 2010
- JCR Allies with GSK for Biosimilars
January 4, 2010
- TAK-085 Enters PIII for Hypertriglyceridemia in Japan: Takeda
January 4, 2010
- Ms Bresch Calls For Generics Promotion Measures Easier for General Consumers to Understand
January 4, 2010
- Novo Nordisk Starts PI for Oral Insulin Analogue in Germany
January 4, 2010
- Chuikyo OKs Measures Proposed by Korosho to Promote Use of Generics
January 4, 2010
- PII of Riociguat for PH-ILD, PH-COPD Completed: Bayer
January 4, 2010
- Premium Decided at 80% of Korosho Proposal, Long-Listed Products to See 2.2% Price Cut
January 4, 2010
- NIBIO to Start Supplying iPS Cells to Private Companies
January 4, 2010
- Ethical Drugs Sales Up 6.2% Driven by Flu Vaccines: Crecon
January 4, 2010
- MOF Demands Double-Digit Cut in Prices of Long-Listed Drugs
January 4, 2010
- Carna Biosciences’Colon Cancer Research Project Subsidized by JST
January 4, 2010
- Takeda Licenses Brentuximab from Seattle Genetics
January 4, 2010
- Health Minister Optimistic about Increases in Medical Fees after Tete-a-Tete with Finance Minister
January 4, 2010
- Nippon Chemiphar, Ranbaxy Terminate Alliance
December 21, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…